- Home
- GOF vs ZLAB Comparison
GOF vs ZLAB Comparison
Compare GOF & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- ZLAB
- Stock Information
- Founded
- GOF 2006
- ZLAB 2013
- Country
- GOF United States
- ZLAB China
- Employees
- GOF N/A
- ZLAB N/A
- Industry
- GOF Finance/Investors Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- GOF Finance
- ZLAB Health Care
- Exchange
- GOF Nasdaq
- ZLAB Nasdaq
- Market Cap
- GOF 2.4B
- ZLAB 3.6B
- IPO Year
- GOF N/A
- ZLAB 2017
- Fundamental
- Price
- GOF $15.08
- ZLAB $32.54
- Analyst Decision
- GOF
- ZLAB Buy
- Analyst Count
- GOF 0
- ZLAB 5
- Target Price
- GOF N/A
- ZLAB $54.28
- AVG Volume (30 Days)
- GOF 789.2K
- ZLAB 781.8K
- Earning Date
- GOF 01-01-0001
- ZLAB 08-05-2025
- Dividend Yield
- GOF 15.42%
- ZLAB N/A
- EPS Growth
- GOF N/A
- ZLAB N/A
- EPS
- GOF N/A
- ZLAB N/A
- Revenue
- GOF N/A
- ZLAB $418,326,000.00
- Revenue This Year
- GOF N/A
- ZLAB $44.07
- Revenue Next Year
- GOF N/A
- ZLAB $49.13
- P/E Ratio
- GOF N/A
- ZLAB N/A
- Revenue Growth
- GOF N/A
- ZLAB 43.72
- 52 Week Low
- GOF $10.96
- ZLAB $16.01
- 52 Week High
- GOF $16.76
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- GOF 66.93
- ZLAB 40.19
- Support Level
- GOF $14.76
- ZLAB $34.26
- Resistance Level
- GOF $15.10
- ZLAB $35.72
- Average True Range (ATR)
- GOF 0.10
- ZLAB 1.12
- MACD
- GOF 0.03
- ZLAB -0.54
- Stochastic Oscillator
- GOF 95.76
- ZLAB 3.83
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.